Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NEJM editorial advocates aspirin therapy for patients with colorectal cancer risk.

This article was originally published in The Tan Sheet

Executive Summary

ASPIRIN USE RECOMMENDED FOR COLORECTAL CANCER AT-RISK POPULATION in an editorial in the Sept.7 issue of the New England Journal of Medicine by Aaron J. Marcus, MD, New York Veterans Affairs Medical Center and Cornell University Medical College. Marcus advised that "people at risk for colorectal cancer -- those with inflammatory bowel disease; breast, ovarian, or endometrial cancer; or a previous adenoma or large-bowel cancer -- should take a single aspirin tablet (325 mg) every other day, barring any contraindication to this medication."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084279

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel